Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC30H33N7O3 |
InChIKeyDSSNAGYVGTYAGH-AREMUKBSSA-N |
CAS Registry3003026-16-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 21 Dec 2022 |